Back to top
more

Cardinal Health (CAH)

(Delayed Data from NYSE)

$113.17 USD

113.17
1,065,517

+0.78 (0.69%)

Updated Sep 13, 2024 04:00 PM ET

After-Market: $113.24 +0.07 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (160 out of 251)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Walgreens' (WBA) AllianceRx Pharmacy Will Distribute VIVJOA

Walgreens' (WBA) specialty pharmacy patients now have exclusive access to 240+ limited distribution drugs.

HealthEquity (HQY) Q4 Earnings Surpass Estimates, Margins Up

HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in the majority of its segments, in the fourth quarter of fiscal 2024.

Here's Why You Should Hold Surmodics (SRDX) Stock for Now

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.

Merit Medical (MMSI) Launches FDA-Cleared Micro-Access System

Merit Medical (MMSI) announces the launch of its latest FDA-approved Micro ACE Advanced Micro-Access System, which is likely to benefit interventional treatments using micro access.

Here's Why You Should Retain Accuray (ARAY) Stock for Now

Accuray's (ARAY) solid product demand raises optimism about the stock.

Here's Why Cardinal Health (CAH) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Investors Should Buy Phibro (PAHC) Stock Now

Phibro's (PAHC) diversified offerings and prospering vaccine business buoy optimism for investors.

Align Technology (ALGN) Gains From Innovation, Macro Issues Ail

In terms of innovation, Align Technology successfully launched its first subscription-based clear aligner program Doctor Subscription Program (DSP) worldwide.

Here's Why Investors Should Retain Abbott (ABT) Stock Now

Investors are optimistic about Abbott (ABT), led by solid prospects in the Diagnostic business and robust adoption of FreeStyle Libre.

Edwards Lifesciences (EW) Up 21.8% YTD: What's Driving It?

Investors are optimistic about Edwards Lifescience's (EW) substantial growth across each of its four product groups.

Inspira Technologies (IINN) Strives to Get AMAR Nod for ART100

The AMAR submission is a strategic move by Inspira Technologies (IINN), positioning it to target global markets with its innovative Augmented Respiration Technology (INSPIRA ART).

Johnson & Johnson (JNJ), Nvidia Unite to Boost AI for Surgery

Johnson & Johnson (JNJ) collaborates with Nvidia to facilitate the creation of AI-based models and the deployment of applications, offering a route to scale within its digital ecosystem for surgery.

Here's Why You Should Retain HealthEquity (HQY) Stock Now

HealthEquity's (HQY) strength in HSAs raises optimism about the stock.

Cencora (COR) Hits 52-Week High: What's Driving the Stock?

Investors are optimistic about Cencora's (COR) strength in the U.S. Healthcare Solutions business.

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

Product innovations and strategic progress bode well for Tandem Diabetes (TNDM).

Here's Why You Should Add Masimo (MASI) to Your Portfolio Now

Masimo's (MASI) R&D activities raise optimism about the stock.

Here's Why You Should Retain Inspire Medical (INSP) Stock Now

Inspire Medical's (INSP) focus on R&D raises optimism about the stock.

Revvity's (RVTY) New Launch to Boost Newborn Sequencing Research

Revvity's (RVTY) next-generation newborn sequencing research workflow is likely to build the foundation for diagnosing rare diseases in the future.

Waters (WAT) Boosts PFAS Testing Solutions With New Cartridges

Waters (WAT) launches Oasis WAX/GCB and GCB/WAX Cartridges for PFAS testing, thus boosting the Waters Operating segment.

High Tide (HITI) Acquires Queen of Bud to Expand Its Portfolio

High Tide (HITI) announces the acquisition of Queen of Bud to boost its in-house cannabis brand portfolio without burdening its significant capital expenditure.

Chemed (CHE) Reaches a New 52-Week High: What's Driving It?

Investors are optimistic about Chemed (CHE) on strong performance across the VITAS and Roto-Rooter segments.

Labcorp (LH) Presents New Research on Precision Diagnostics

Labcorp's (LH) new research shows how biomarker testing can help close testing gaps and guide tailored therapy for patients with epithelial ovarian cancer.

Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

Boston Scientific (BSX) Global Growth Robust, Macro Issues Ail

Boston Scientific (BSX) is consistently registering fast recovery within its MedSurg segment in the post-pandemic period.

PetIQ (PETQ) Broadens Minties Line With Large Dogs Dental Treats

PetIQ (PETQ), with a focus on affordability and natural ingredients, is well-positioned to meet the evolving needs of pet owners and continue its growth trajectory in the pet wellness market.